Colorectal cancer
Conditions
Interventions
None listed
Sponsors
Japan Clinical Cancer Research Organization
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Metastatic colorectal cancer. (2) In the case of advanced colorectal cancer. 1-1) Case of StageIV resected the primary lesion. 1-2) RAS genetic-tested or KRAS genetic-tested using a tumor tissue paraffin-embedded block of the primary lesion. i) RAS mutant-type or KRAS mutant-type ii) RAS wild-type In the case of recurrence colorectal cancer. 2-1) Case of StageI-III resected the primary lesion within 2 years. 2-2) The recurrence was confirmed after primary lesion excision. 2-3) RAS genetic-tested or KRAS genetic-tested using a tumor tissue paraffin-embedded block of the primary lesion. i) RAS mutant-type or KRAS mutant-type ii) RAS wild-type (3) Patients who can provide a tumor tissue paraffin-embedded block of the primary lesion. (4) Written informed consent.
Exclusion criteria
Exclusion criteria: (1) Patients who received neoadjuvant chemotherapy . (2) Patients who are regarded as inadequate for study enrollment by investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The HER2-positive ratio by the IHC method, the FISH method and the HERmark method | — |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate the sensitivity of the HERmark method. To examine the relationship between the HER2 expression and the background factor. | — |
Countries
Japan
Contacts
Public ContactMasashi Fujii
Japan Clinical Cancer Research Organization Office
Outcome results
None listed